Understanding SARS-CoV-2 and Host Immune Response to COVID-19 with PacBio Sequencing

For Research Use Only. Not for use in diagnostics procedures.
© Copyright 2020 by Pacific Biosciences of California, Inc. All rights reserved. 
1305 O'Brien Rd., Menlo Park, CA 94025   |  Legal & Trademarks

By registering on this web page, you are consenting and agreeing to collection and use of that information by PacBio in accordance with its Privacy Policy.

With the COVID-19 global pandemic, there is an urgent need to advance genetic research into the novel coronavirus (SARS-CoV-2), including testing, transmission, treatment, and the immunology and epidemiology of host immune response.   

Highly accurate long-read sequencing provides multiple benefits for COVID-19 research, including full-length viral RNA reference genomes for SARS-CoV-2 isolates.

Join us to hear directly from research scientists discussing these long-read sequencing applications — including methods, case study results, and new assays for SARS-CoV-2 and COVID-19 that are now under development.

Attend this webinar to understand:

  • How highly accurate long reads can help with sequencing SARS-CoV-2
  • Protocols for genetic mutation profiling in SARS-CoV-2 viral RNA isolates
  • The advantages of long-read sequencing for BCR profiling and inference-free genotyping of the IGH locus for understanding variation in antibody-mediated immunty, which may be of relevance to the current pandemic
  • Methods for imputation-free long-read sequencing of the HLA loci, highly polymorphic mediators of the human adaptive immune response that have been linked to increased resistance or susceptibility to infectious diseases


Melissa Laird-Smith, Ph.D. 
Assistant Professor of Genetics and Genome Sciences
Mt. Sinai

Talk: Evaluating the Impact of Host Immune Restriction in Health and Disease with High Resolution HLA Typing


Corey T. Watson, Ph.D.
Assistant Professor
University of Louisville School of Medicine

Talk: Overcoming Complexity to Elucidate the Role of IGH Haplotype Diversity in Antibody-mediated Immunity

Meredith Ashby, Ph.D.
Director, Market Strategy for Microbial and Cancer Genomics